Q-omics provides the consensus-scored TNRC6B profile across patient tissues and cancer cell-line models. TNRC6B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, TNRC6B is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, TNRC6B RNA expression shows 22,092 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, THCA, and ACC as cancer lineages where TNRC6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNRC6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNRC6B survival associations across molecular data types. TNRC6B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNRC6B RNA expression–survival associations across cancer types. High TNRC6B expression shows unfavorable associations in ACC, but favorable associations in SCLC, HNSC, LUSC, UCS and ESCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for TNRC6B RNA expression.
This table summarizes TNRC6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TNRC6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNRC6B shows lower tumor expression in THCA and BRCA and higher tumor expression in LIHC, HNSC, CHOL and LUSC. The THCA box plot shows higher TNRC6B RNA expression in normal versus tumor tissue (log2 FC = −0.625, t-test p < 0.001).
This table shows molecular features associated with TNRC6B in patient tissues and cancer cell lines. In patient samples, TNRC6B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNRC6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
